Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIM-23458
- Development stage
- Unknown
- Lead developer
- University of Toronto
- Modality
- Peptides
- Administration
- Intraperitoneal, Intravenous
01
Overview
BIM-23458 (also known as PRL-2903) is a selective peptide antagonist of the somatostatin receptor type 2 (SSTR2). It was synthesized by Dr. David H. Coy at Tulane University and has been investigated in preclinical models of diabetes. By blocking SSTR2, BIM-23458 prevents somatostatin-mediated inhibition of glucagon secretion from pancreatic alpha-cells, thereby restoring the glucagon and corticosterone counterregulatory responses to insulin-induced hypoglycemia. It serves as a prototype SSTR2 antagonist for the prevention of hypoglycemia in type 1 diabetes.
- Other names
- H-Fpa-cyclo(DCys-Pal-DTrp-Lys-Tle-Cys)-Nal-NH2H-Fpa-cyclo[DCys-Pal-DTrp-Lys-Tle-Cys]-Nal-NH2somatostatin receptor type 2 antagonistSSTR2aSSTR-2aSSTR 2a
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on BIM-23458.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIM-23458.